文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

幽门螺杆菌根除后萎缩性胃炎和肠上皮化生的可逆性——一项长达10年的前瞻性研究

Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years.
PubMed 文献 · Aliment Pharmacol Ther · 2017-11-29

这项前瞻性研究纳入598名受试者随访长达10年,分为幽门螺杆菌阴性组65例、未根除组91例和根除组442例,按悉尼分类进行组织学评估。结果显示,仅根除组胃窦和胃体萎缩性胃炎及肠上皮化生较基线显著改善(各时间点均P<.05),根除组与阴性组在萎缩性胃炎上的显著差异从1年随访起消失。结论认为幽门螺杆菌根除可能通过萎缩性胃炎和肠上皮化生的消退成为肠型胃癌的预防策略。

要点

  • 仅幽门螺杆菌根除组胃窦和胃体萎缩性胃炎较基线显著改善,各时间点均P<.05。
  • 仅根除组胃窦和胃体肠上皮化生较基线显著改善,各时间点均P<.05。
  • 根除组与阴性组萎缩性胃炎的显著差异从1年随访起消失。

核心结论

  • 幽门螺杆菌根除可能通过萎缩性胃炎和肠上皮化生的消退成为肠型胃癌的预防策略。

研究设计与样本

  • 前瞻性研究纳入598名受试者,随访长达10年,分为幽门螺杆菌阴性组65例、未根除组91例和根除组442例。
  • 对胃窦和胃体按悉尼分类进行组织学评估,随访时间点包括1年、2年、3-4年和≥5年。

主要发现

  • 组织学随访平均时间分别为1.07±0.21年、2.29±0.83年、3.93±1.02年和6.45±1.28年。
  • 胃窦和胃体萎缩性胃炎仅在根除组较基线逐渐且显著改善,各时间点均P<.05。
  • 根除组与阴性组萎缩性胃炎的显著差异从1年随访起消失。
  • 胃窦和胃体肠上皮化生仅在根除组较基线显著改善,各时间点均P<.05。
  • 根除组与阴性组肠上皮化生的显著差异在胃窦从≥5年随访起消失,在胃体从3年随访起消失。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atrophic gastritis and intestinal metaplasia are premalignant conditions for gastric cancer. Their reversibility by Helicobacter pylori eradication remains controversial. AIM: To evaluate the reversibility of atrophic gastritis and intestinal metaplasia by H. pylori eradication with long-term follow-up. METHODS: 598 subjects were prospectively enrolled and followed for up to 10 years. They were categorised as H. pylori-negative (n = 65), H. pylori non-eradicated (n = 91), and H. pylori-eradicated (n = 442). Histological assessment was performed for antrum and corpus by Sydney classification. RESULTS: Histological follow-up was performed regularly at 1, 2, 3-4 and ≥5 years, with mean follow-up of 1.07 ± 0.21, 2.29 ± 0.83, 3.93 ± 1.02, and 6.45 ± 1.28 years, respectively. Atrophic gastritis in antrum and corpus gradually and significantly (both P < .05 for all timepoints) improved only in the H. pylori-eradicated group compared to that at baseline. Significant difference in atrophic gastritis between H. pylori-eradicated and H. pylori-negative groups disappeared from 1-year follow-up. Similarly, intestinal metaplasia in antrum and corpus improved significantly (both P < .05 for all timepoints) only in the H. pylori-eradicated group in comparison with that at baseline. Significant difference in intestinal metaplasia between H. pylori-eradicated and H. pylori-negative groups disappeared from ≥5 years of follow-up in the antrum and from 3 years of follow-up in the corpus. CONCLUSION: H. pylori eradication may be a preventative strategy for intestinal-type gastric cancer by regression of atrophic gastritis and intestinal metaplasia.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hwang YJ, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther. 2017. PMID: 29193217. doi:10.1111/apt.14424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。